Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Picks Paul’s Brain: CNS Researcher To Succeed R&D Head Watanabe

Executive Summary

Lilly R&D president-elect Steven Paul, MD, will bring an extensive background in central nervous system discovery and research to Lilly's top research position

You may also be interested in...



Lilly Elevates Santini To Senior VP; “Access & Policy” Are Priorities

Lilly is placing additional emphasis on prescription drug access and pricing issues with the appointment of U.S. Operations President Gino Santini to senior VP-corporate strategy and policy

Lilly Elevates Santini To Senior VP; “Access & Policy” Are Priorities

Lilly is placing additional emphasis on prescription drug access and pricing issues with the appointment of U.S. Operations President Gino Santini to senior VP-corporate strategy and policy

Lilly R&D personnel changes

Leader of Lilly's Zyprexa product team and clinical research fellow Alan Breier, MD, assumes Chief Medical Officer and VP-Medical position; Breier replaces Michael McDonald, MD, who is leaving Lilly. VP-Clinical Research and U.S. Regulatory Affairs and Policy Tim Franson, MD, replaces Michael Clayman, MD, as VP-Global Regulatory Affairs; Clayman moves into the new position of VP-Lilly Research Laboratories. Breier and Franson report to Steven Paul, MD, recently appointed R&D president (1"The Pink Sheet" May 19, 2003, p. 16)...

Related Content

UsernamePublicRestriction

Register

PS041815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel